Is an international randomized double-blind placebo-controlled trial of anti-influenza hyperimmune intravenous immunoglobulin (IVIG) in individuals hospitalized with influenza (flu) A or B.
The primary objective is to determine whether, when added to standard of care (SOC) treatment, IVIG helps reduce the severity and duration of flu symptoms.
FLU-IVIG is expected to enroll approximately 320 participants at up to 40 sites in the US, Europe, South America, and Australasia.
Each participant is followed for approximately 28 days.
FLU-IVIG EudraCT number: 2014-004271-22
For further details about the Influenza studies, please visit the INSIGHT website.